You are here

Arena Pharmaceuticals

Why Arena Pharmaceuticals' Q2 Results Don't Matter

Why Arena Pharmaceuticals' Q2 Results Don't Matter

Motley Fool

Arena Pharmaceuticals

Flag link:

Only 1 Number Mattered in Arena Pharmaceuticals' Q3 Results -- and It Was Big

Only 1 Number Mattered in Arena Pharmaceuticals' Q3 Results -- and It Was Big

Motley Fool

Arena Pharmaceuticals

Flag link:

Arena Pharmaceuticals’ Selective CB2 Receptor Activator Drug Candidate Fights Pain in Irritable Bowel Syndrome

Arena Pharmaceuticals’ Selective CB2 Receptor Activator Drug Candidate Fights Pain in Irritable Bowel Syndrome

Xtalks

Arena Pharmaceuticals

cannabinoid type 2 receptors

Flag link:

Arena’s Comeback Continues with $800M Deal for Blood Disease Drug

Arena’s Comeback Continues with $800M Deal for Blood Disease Drug

Xconomy

Arena Pharmaceuticals

United Therapeutics

Flag link:

Arena 3 for 3 as Crohn’s drug meets proof-of-concept test

Arena 3 for 3 as Crohn’s drug meets proof-of-concept test

Fierce Biotech

Arena Pharmaceuticals

Crohn's Disease

Flag link:

3 Biotech Stocks That Skyrocketed This Week

3 Biotech Stocks That Skyrocketed This Week

Motley Fool

Arena Pharmaceuticals

Heron Therapeutics

Flag link:

Arena Pharmaceuticals Takes Aim at Celgene

Arena Pharmaceuticals Takes Aim at Celgene

Motley Fool

Arena Pharmaceuticals

ulcerative colitis

Flag link:

Here's Why Arena Pharmaceuticals, Inc. Surged Again on Wednesday

Here's Why Arena Pharmaceuticals, Inc. Surged Again on Wednesday

Motley Fool

Arena Pharmaceuticals

ulcerative colitis

Flag link:

Celgene's Future Growth Could Depend on a Competitor's Trial This Quarter

Celgene's Future Growth Could Depend on a Competitor's Trial This Quarter

Motley Fool

Arena Pharmaceuticals

multiple sclerois

Flag link:

Three Interviews From the J.P. Morgan Healthcare Conference

Three Interviews From the J.P. Morgan Healthcare Conference

Motley Fool

Arena Pharmaceuticals

Spark Therapeutics

Flag link:

Here's What Lifted Arena Pharmaceuticals, Inc. Stock in September

Here's What Lifted Arena Pharmaceuticals, Inc. Stock in September

Motley Fool

Arena Pharmaceuticals

pulmonary arterial hypertension

Flag link:

Arena Pharma Skyrockets on Heart Disease Data, Stock Could Still Double -Firm Says

Arena Pharma Skyrockets on Heart Disease Data, Stock Could Still Double -Firm Says

TheStreet.com

Arena Pharmaceuticals

pulmonary arterial hypertension

Flag link:

Arena takes a big step down the comeback trail with PhII success, shares rocket up

Arena takes a big step down the comeback trail with PhII success, shares rocket up

Endpoints

Arena Pharmaceuticals

clinical trials

pulmonary arterial hypertension

Flag link:

Here's Why Arena Pharmaceuticals Rose as Much as 18.3% Friday

Here's Why Arena Pharmaceuticals Rose as Much as 18.3% Friday

Motley Fool

Arena Pharmaceuticals

Flag link:

Arena Pharmaceuticals beats 4Q profit forecasts

Arena Pharmaceuticals beats 4Q profit forecasts

Yahoo/AP

Arena Pharmaceuticals

Flag link:

Arena Turns Page On Belviq - Restructures Deal With Eisai

Arena Turns Page On Belviq - Restructures Deal With Eisai

Seeking Alpha

Arena Pharmaceuticals

Flag link:

Arena Pharmaceuticals reports 3Q loss

Arena Pharmaceuticals reports 3Q loss

Yahoo/AP

Arena Pharmaceuticals

Flag link:

Drug maker faces a shareholder suit for failing to tell the whole truth

Drug maker faces a shareholder suit for failing to tell the whole truth

Stat/Pharmalot

Arena Pharmaceuticals

Flag link:

Eisai Inc. and Arena Pharmaceuticals Announce Availability of Once-Daily BELVIQ XR® (lorcaserin HCl) Extended-Release Tablets

Eisai Inc. and Arena Pharmaceuticals Announce Availability of Once-Daily BELVIQ XR® (lorcaserin HCl) Extended-Release Tablets

Yahoo

Arena Pharmaceuticals

Flag link:

Arena Launches Drug Discovery Incubator (ARNA)

Arena Launches Drug Discovery Incubator (ARNA)

Investopedia

Arena Pharmaceuticals

Beacon Discovery

Flag link:

Pages